Disease, Disability, and Injury Prevention and Control, 7606 [2010-3146]
Download as PDF
<![CDATA[
7606
Federal Register / Vol. 75, No. 34 / Monday, February 22, 2010 / Notices
FDA’s burden estimate is based on
prior experience with Internet panel
experiments similar to the study
proposed here. Sixty panel members
will take part in a pre-test of the study,
estimated to last 30 minutes (0.5 hours),
for a total of 30 hours. Approximately
15,000 respondents will complete a
screener to determine eligibility for
participation in the study, estimated to
take 1 minute (0.016 hours), for a total
of 125 hours. Fifty-four hundred (5,400)
respondents will complete the full
study, estimated to last 30 minutes (0.5
hours), for a total of 2,700 hours. The
total estimated burden is 2,970 hours.
[FR Doc. 2010–3148 Filed 2–19–10; 8:45 am]
[FR Doc. 2010–3320 Filed 2–19–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention (CDC): Notice of Charter
Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Advisory Committee to the Director,
Centers for Disease Control and
Prevention of the Department of Health
and Human Services, has been renewed
for a 2-year period extending through
February 1, 2012.
Contact Person for More Information:
Anne C. Haddix, PhD, Designated
Federal Officer, ACD, CDC, 1600 Clifton
Road, NE., M/S D14, Atlanta, Georgia
30333. Telephone 404–639–0663.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Jkt 220001
[Docket No. FDA–1996–N–0006] (formerly
Docket No. 1996N–0277)
Safety and Efficacy Review for
Additional Ingredients in Over-theCounter Drug Products for Human
Use; Request for Environmental
Impact Data and Information
AGENCY:
Food and Drug Administration,
HHS.
Disease, Disability, and Injury
Prevention and Control
ACTION: Request for data and
information.
SUMMARY: We (Food and Drug
Administration (FDA)) are requesting
data and information regarding the
potential environmental impact of
amending over-the-counter (OTC) drug
monographs to include certain active
ingredients not previously marketed in
the United States or marketed in the
United States under approved
applications after the OTC drug review
began in 1972. Thirteen active
ingredients have been found eligible for
potential inclusion in OTC drug
monographs based on time and extent
applications (TEAs). We are currently
evaluating the safety and effectiveness
of these ingredients.
DATES: Submit data, information, and
general comments by May 24, 2010.
ADDRESSES: Submit electronic or written
data, information, and general
comments in response to this document.
Submit electronic comments to https://
regulations.gov. Submit written
comments to the Division of Dockets
Management HFA–305), 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Michael L. Koenig, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 5411,
Silver Spring, MD 20993–0002, 301–
796–2090.
SUPPLEMENTARY INFORMATION:
Time and Date: 1 p.m.–3 p.m., April 20,
2010 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Healthy Passages Longitudinal
Study of Youth, FOA DP 10–007.’’
Contact Person for More Information:
Michael Dalmat, DRPH., Scientific Review
Officer, National Center for Chronic Disease
and Health Promotion, Office of the Director,
Extramural Research Program Office, 4770
Buford Highway, NE., Mailstop K–92,
Atlanta, GA 30341, Telephone: (770) 488–
6423, E-mail: MED1@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: February 10, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
BILLING CODE 4163–18–P
15:26 Feb 19, 2010
Food and Drug Administration
BILLING CODE 4163–18–P
[FR Doc. 2010–3146 Filed 2–19–10; 8:45 am]
VerDate Nov<24>2008
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Special Emphasis Panel (SEP):
Healthy Passages Longitudinal Study of
Youth, Funding Opportunity
Announcement (FOA) DP 10–007,
Initial Review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Dated: February 16, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
cprice-sewell on DSK2BSOYB1PROD with NOTICES
Dated: February 11, 2010.
Andre Tyler,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
I. Ingredients Affected by This Notice
We are currently evaluating the safety
and effectiveness of 13 active
ingredients found eligible for possible
addition to an OTC drug monograph via
the TEA process described in 21 CFR
330.14. The ingredients under review
are shown in table 1 of this document:
E:\FR\FM\22FEN1.SGM
22FEN1
]]>Agencies
[Federal Register Volume 75, Number 34 (Monday, February 22, 2010)]
[Notices]
[Page 7606]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-3146]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel (SEP): Healthy Passages Longitudinal Study
of Youth, Funding Opportunity Announcement (FOA) DP 10-007, Initial
Review.
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Time and Date: 1 p.m.-3 p.m., April 20, 2010 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the initial
review, discussion, and evaluation of applications received in
response to ``Healthy Passages Longitudinal Study of Youth, FOA DP
10-007.''
Contact Person for More Information: Michael Dalmat, DRPH.,
Scientific Review Officer, National Center for Chronic Disease and
Health Promotion, Office of the Director, Extramural Research
Program Office, 4770 Buford Highway, NE., Mailstop K-92, Atlanta, GA
30341, Telephone: (770) 488-6423, E-mail: MED1@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: February 10, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2010-3146 Filed 2-19-10; 8:45 am]
BILLING CODE 4163-18-P
